Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. - Wikidata - wikimedia - TriplyDB

Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

http://www.wikidata.org/entity/Q33853335

about

Myotonic disorders: A review article Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions Noncoding RNAs: emerging players in muscular dystrophies Therapeutics development in myotonic dystrophy type 1.ClC-1 chloride channels: state-of-the-art research and future challenges.Mechanisms and management of the heart in myotonic dystrophy.Measuring quality of life impairment in skeletal muscle channelopathies.A quantitative measure of handgrip myotonia in non-dystrophic myotonia Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial Chronic muscle stimulation improves muscle function and reverts the abnormal surface EMG pattern in myotonic dystrophy: a pilot study Myotonic dystrophy health index: Correlations with clinical tests and patient function The diagnosis and treatment of myotonic disorders.Structure and Dynamics of RNA Repeat Expansions That Cause Huntington's Disease and Myotonic Dystrophy Type 1.Different electrophysiological effects of the levo- and dextro-rotatory isomers of mexiletine in isolated rabbit cardiac muscle.Myotonic Dystrophy Type 1 Management and Therapeutics.Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine.Myotonic dystrophy type 1.Chloride channel dysfunction study in myotonic dystrophy type 1 using repeated short exercise tests.Sodium Channel Inhibitors Reduce DMPK mRNA and Protein.Voxel-based diffusion tensor imaging of an APP/PS1 mouse model of Alzheimer's disease.The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study.Direct Aryl C-H Amination with Primary Amines Using Organic Photoredox Catalysis.Quantitative sonographic assessment of myotonia.Dual Action of Mexiletine and Its Pyrroline Derivatives as Skeletal Muscle Sodium Channel Blockers and Anti-oxidant Compounds: Toward Novel Therapeutic Potential.Characterization of Four New Distinct ω-Transaminases from Pseudomonas putida NBRC 14164 for Kinetic Resolution of Racemic Amines and Amino Alcohols.Treating pediatric neuromuscular disorders: The future is now.The anti-convulsants lacosamide, lamotrigine, and rufinamide reduce myotonia in isolated human and rat skeletal muscle.

P2860

Q26747746-926BA00D-4ACE-4287-9315-1B5230F0C80B Q26777206-ACA115B1-289F-4FCB-9F6F-B8530289B4A2 Q26996781-69541A04-405B-42F9-90B6-684E971AB912 Q30425796-FFECCA93-27D5-4231-A490-1D569E728D4E Q35541006-48F036AB-70D2-4BD6-A907-917C32A2C377 Q36069666-D5B890F6-BD7D-44CA-AD4E-D0825D7395E2 Q36382734-C99BEE48-2FF1-4D1E-9E3A-E72636E212CE Q36587121-2FB9586A-9D29-415F-A72A-EACCD4E5E9B1 Q36587149-0243074E-B755-4C7F-ACF7-43884F13555F Q37152085-7760C7E3-18DA-4E19-A0F3-611D27AF5CE3 Q37165392-69B7B569-2BD9-4526-9132-E78F815494FB Q38093802-D5666E32-61EF-400F-BF21-659155FE41B6 Q38430517-BC05E633-27E8-4FC3-96AE-9BCC548B776C Q38947957-77E91FAD-DBD9-4A6C-89CD-BA09B59A7478 Q39003493-BAC71479-D855-45E5-B36B-045B562B85F3 Q39016920-44FDFF61-B387-40B8-B17B-65A87E4D3580 Q40376134-A7671C34-A435-442F-9D06-452DFA07B310 Q40715212-872184AA-EB9D-444A-8814-8231DCCF6E7E Q41055497-E69BF50B-67B3-4774-9AA1-971D833AC85D Q42316379-AA88B910-1D70-40C0-81EF-859E4BF04FD7 Q47955259-0B864B4F-FDDC-4EB0-925B-0BA433D28653 Q48011157-8D488DD9-0EF2-4671-8006-DF1B3333BAB2 Q48140392-5A8547EA-8064-4E8D-9C4F-C195A77A9097 Q48351231-7AE35284-7090-46D5-A1ED-E1E159AC2C70 Q49209350-3F3F1CA0-AD5F-4706-B77F-57C75F534E65 Q51142708-6B62FF2E-044F-49D3-88F7-EA362CBC6293 Q52756417-77FE1098-6F8A-4D96-8AE1-B6D3D4436F6D Q54464202-68537F4D-B455-49C8-9BC9-3C375884D355

P2860

Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

http://www.wikidata.org/entity/Q33853335

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

@ast

Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

@en

type

label

Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

@ast

Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

@en

prefLabel

Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

@ast

Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

@en

P1433

Q33853335-60268811-BD9D-4444-9A50-11A366289276

P1476

Q33853335-6CF93A23-0448-415B-B94A-F6C6EB052B08

P2093

Q33853335-0925C7A2-44AC-48E2-BA49-3442E24B40D2

Q33853335-4C0FFBEA-7373-450B-A14B-BC172EC37310

Q33853335-88D9A5DE-E54E-4E74-B74B-13FF1C8E0AAD

Q33853335-9A60C129-6D9E-48ED-98EF-09DD2B184553

Q33853335-AC21230C-EBD3-4309-B2E5-843541D49F88

Q33853335-BD1A1681-D8AD-4333-8135-ABF9FF84291B

Q33853335-C9B6311C-C68B-496B-961D-93CC1517B389

Q33853335-D8F12FA3-2B16-4D0C-B33C-9AB0561C44F5

Q33853335-F264E204-ED2E-4E25-B90F-F113847D212C

Q33853335-FC05218E-55B2-4413-BBB2-C83A4A75D138

P2860

Q33853335-0B93BBA1-256B-4CF4-9A50-F41F7043A2D9

Q33853335-1B7336D0-C100-4458-AFA2-18DF7C2D2F89

Q33853335-2896286E-EE7D-48BA-8C25-C11386BC4A5D

Q33853335-4F5BD77E-6699-400C-BAF2-CB2A7BF6D476

Q33853335-6989172A-45A0-4233-A9FE-9733EECB65CA

Q33853335-710D911C-2458-451A-BECB-A671D00E84EE

Q33853335-74488681-7226-4268-9813-9E0AA5A40025

Q33853335-78A32988-5D71-4679-BB53-71635C3E6983

Q33853335-7D26069C-25E4-4EA3-B9CC-077614D13160

Q33853335-93BB6588-D8D8-497A-9A9B-DB9C4B1A84C9

P304

Q33853335-EDA0223C-83E5-47CC-9007-E48C09C77E5E

P31

Q33853335-0D93B28A-CE57-4245-9AA6-5EBD53D4677E

P356

Q33853335-61E05D49-111D-43B9-BD7F-F5B81AE85B20

P407

Q33853335-79987E14-CEF8-4175-A5E2-09CFB727F6A0

P433

Q33853335-45A40823-9A11-47A7-B987-25B261D1D133

P478

Q33853335-F8ABB6E4-E0D3-4EB4-B9E1-33F136EA64AB

P50

Q33853335-1DEDA9D6-9F6A-46A4-A5B2-88559E394C83

P577

Q33853335-3CFC13E3-B32E-4E29-A34E-D1D333E7B966

P5875

Q33853335-F8766AD4-5ADF-4441-AC23-087668B31CB4

P698

Q33853335-4240ED74-644E-4ECD-8ACE-2466ABB2C460

P932

Q33853335-B690C806-7209-4B8D-9AD5-3BCCB1F80DAC

P356

WNL.0B013E3181DC1A3A

P1433

P1476

Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1

@en

P2093

A W Wiegner

http://www.w3.org/2001/XMLSchema#string

C A Barbieri

http://www.w3.org/2001/XMLSchema#string

C A Thornton

http://www.w3.org/2001/XMLSchema#string

C L Annis

http://www.w3.org/2001/XMLSchema#string

E L Logigian

http://www.w3.org/2001/XMLSchema#string

M P McDermott

http://www.w3.org/2001/XMLSchema#string

N Dilek

http://www.w3.org/2001/XMLSchema#string

R T Moxley

http://www.w3.org/2001/XMLSchema#string

W B Martens

http://www.w3.org/2001/XMLSchema#string

P2860

Drug treatment for myotonia

Nifedipine in the treatment of myotonia in myotonic dystrophy.

Mexiletine block of disease-associated mutations in S6 segments of the human skeletal muscle Na(+) channel

Voltage-gated ion channels and hereditary disease.

Spectrum of sodium channel disturbances in the nondystrophic myotonias and periodic paralyses.

An unstable triplet repeat in a gene related to myotonic muscular dystrophy.

Human muscle voltage-gated ion channels and hereditary disease.

Successuful treatment of paramyotonia congenita (Eulenburg): muscle stiffness and weakness prevented by tocainide

Preferred mexiletine block of human sodium channels with IVS4 mutations and its pH-dependence.

P304

1441-1448

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0B013E3181DC1A3A

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Alexander T Pearson

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44570745

http://www.w3.org/2001/XMLSchema#string

P698

20439846

http://www.w3.org/2001/XMLSchema#string

P932

2871004

http://www.w3.org/2001/XMLSchema#string